Article

The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays

2023-03-15

Abstract excerpt

<h4>SUMMARY</h4> CDK4/6 inhibitors arrest the cell cycle in G1 and are used in combination with hormone therapy to treat advanced HR+/HER- breast cancer. To allow more effective use of these drugs in breast cancer, and to facilitate their use in other tumour types, biomarkers that can predict response are urgently needed. We demonstrate here that previous large-scale screens designed to identify the most sensitiv...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2800d613-907b-5d22-8788-09908d0f5c8e
DOI: 10.1101/2023.03.15.532719

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assaysDOI 10.1101/2023.03.15.532719Read

The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assaysSemantic proximity Read

Chemoproteomic Evaluation of Target Engagement by the Cyclin-Dependent Kinase 4 and 6 Inhibitor Palbociclib Correlates with Cancer Cell ResponseSemantic proximity Read

Biological specificity of CDK4/6 inhibitors: dose response relationship,in vivosignaling, and composite response signatureSemantic proximity Read

The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancerSemantic proximity Read

Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017Semantic proximity Read

Efficient inhibition of cell proliferation and promotion of apoptosis requires continuous treatment with abemaciclibSemantic proximity Read

Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2Semantic proximity Read

Exploiting collateral sensitivity controls growth of mixed culture of sensitive and resistant cells and decreases selection for resistant cellsSemantic proximity Read

Single-cell transcriptomics reveals biomarker heterogeneity linked to CDK4/6 Inhibitor resistance in breast cancer cell linesSemantic proximity Read

Functional Genomic Analysis of CDK4 and CDK6 Gene Dependency across Human Cancer Cell LinesSemantic proximity Read

Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast CancerSemantic proximity Read

Acquired resistance to CDK4/6 inhibition is associated with dysregulation of multiple pathways including cyclin D-CDK4/6-RB, EGFR/HER, AKT/mTOR and IFN signalingSemantic proximity Read